CoChat
Sign Up
Cited by 671Inflammasome and immune disordersImmune Response and InflammationAutoimmune and Inflammatory Disorders Research

Pharmacological Inhibitors of the NLRP3 Inflammasome

Open access
Zahid, Ayesha, Li, Bofeng, Kombe, Arnaud John Kombe, Jin, Tengchuan, Tao, Jinhui·2019·Frontiers in Immunology
DOI 10.3389/fimmu.2019.02538PMC PMC6842943
Open this paper in CoChat — free accountOpen PDF

Abstract

Inflammasomes play a crucial role in innate immunity by serving as signaling platforms which deal with a plethora of pathogenic products and cellular products associated with stress and damage. By far, the best studied and most characterized inflammasome is NLRP3 inflammasome, which consists of NLRP3 (nucleotide-binding domain leucine-rich repeat (NLR) and pyrin domain containing receptor 3), ASC (apoptosis-associated speck-like protein containing a caspase recruitment domain), and procaspase-1. Activation of NLRP3 inflammasome is mediated by highly diverse stimuli. Upon activation, NLRP3 protein recruits the adapter ASC protein, which recruits the procaspase-1 resulting in its cleavage and activation, inducing the maturation and secretion of inflammatory cytokines and pyroptosis. However, aberrant activation of the NLRP3 inflammasome is implicated in various diseases including diabetes, atherosclerosis, metabolic syndrome, cardiovascular and neurodegenerative diseases; raising a tremendous clinical interest in exploring the potential inhibitors of NLRP3 inflammasome. Recent investigations have disclosed various inhibitors of the NLRP3 inflammasome pathway which were validated through in vitro studies and in vivo experiments in animal models of NLRP3-associated disorders. Some of these inhibitors directly target the NLRP3 protein whereas some are aimed at other components and products of the inflammasome. Direct targeting of NLRP3 protein can be a better choice because it can prevent off target immunosuppressive effects, thus restrain tissue destruction. This paper will review the various pharmacological inhibitors of the NLRP3 inflammasome and will also discuss their mechanism of action.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fimmu.2019.02538

Cites

0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The NLRP3 inflammasome is a key regulator of SASP induction, widely involved in disease and for which drug development is active.

    “the NLRP3 inflammasome is a key regulator of SASP induction, widely involved in disease and for which drug development is active (Zahid et al. 2019).”

    From Senescence and the SASP: many therapeutic avenues (2020) · cites this paper as Zahid et al. 2019

    The “NLRP3 Inflammasome Associated Diseases” section links NLRP3 activation to numerous diseases, and “Pharmacological Inhibition of NLRP3 Inflammasome” describes active investigation of inhibitors. The paper describes NLRP3-driven inflammatory cytokine release, but the passages do not identify it as a key regulator of SASP induction (searched: SASP, senescence, secretory phenotype). (LLM, conf=0.87)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 109

  1. [1]Neill DR Wong SH Bellosi A Flynn RJ Daly M Langford TK. Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. Nature. (2010) 464: 1367– 70. 10.1038/nature08900 20200518 PMC2862165 · DOI
  2. [2]Fullard N O'Reilly S. Role of innate immune system in systemic sclerosis. Semin Immunopathol. (2015) 37: 511– 7. 10.1007/s00281-015-0503-7 26159672 · DOI
  3. [3]Martinon F Burns K Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-β. Mol Cell. (2002) 10: 417– 26. 10.1016/S1097-2765(02)00599-3 12191486 · DOI · Paper page
  4. [4]Sanders M Parsons M Howard A Liu J Fassio S Martinez J. Single-cell imaging of inflammatory caspase dimerization reveals differential recruitment to inflammasomes. Cell Death Dis. (2015) 6: e1813. 10.1038/cddis.2015.186 26158519 PMC4650733 · DOI
  5. [5]Schroder K Tschopp J. The inflammasomes. Cell. (2010) 140: 821– 32. 10.1016/j.cell.2010.01.040 20303873 · DOI · Paper page
  6. [6]Minkiewicz J de Rivero Vaccari JP Keane RW. Human astrocytes express a novel NLRP2 inflammasome. Glia. (2013) 61: 1113– 21. 10.1002/glia.22499 23625868 · DOI
  7. [7]Inoue M Shinohara ML. The role of interferon-β in the treatment of multiple sclerosis and experimental autoimmune encephalomyelitis–in the perspective of inflammasomes. Immunology. (2013) 139: 11– 8. 10.1111/imm.12081 23360426 PMC3634535 · DOI
  8. [8]Ito M Shichita T Okada M Komine R Noguchi Y Yoshimura A. Bruton's tyrosine kinase is essential for NLRP3 inflammasome activation and contributes to ischaemic brain injury. Nat Commun. (2015) 6: 7360. 10.1038/ncomms8360 26059659 PMC4490404 · DOI
  9. [9]Inoue M Shinohara ML. Nlrp3 inflammasome and MS/EAE. Autoimmune Dis. (2013) 2013: 859145. 10.1155/2013/859145 23365725 PMC3556409 · DOI
  10. [10]Zhong Y Kinio A Saleh M. Functions of NOD-like receptors in human diseases. Front Immunol. (2013) 4: 333. 10.3389/fimmu.2013.00333 24137163 PMC3797414 · DOI
  11. [12]Duncan JA Bergstralh DT Wang Y Willingham SB Ye Z Zimmermann AG. Cryopyrin/NALP3 binds ATP/dATP, is an ATPase, and requires ATP binding to mediate inflammatory signaling. Proc Natl Acad Sci USA. (2007) 104: 8041– 6. 10.1073/pnas.0611496104 17483456 PMC1876568 · DOI
  12. [13]Sharif H Wang L Wang WL Magupalli VG Andreeva L Qiao Q. Structural mechanism for NEK7-licensed activation of NLRP3 inflammasome. Nature. (2019) 570: 338– 43. 10.1038/s41586-019-1295-z 31189953 PMC6774351 · DOI · Paper page
  13. [14]Franchi L Muñoz-Planillo R Núñez G. Sensing and reacting to microbes through the inflammasomes. Nat Immunol. (2012) 13: 325– 32. 10.1038/ni.2231 22430785 PMC3449002 · DOI
  14. [15]Doyle SL Campbell M Ozaki E Salomon RG Mori A Kenna PF. NLRP3 has a protective role in age-related macular degeneration through the induction of IL-18 by drusen components. Nat Med. (2012) 18: 791– 8. 10.1038/nm.2717 22484808 PMC3984677 · DOI
  15. [19]Martín-Sánchez F Diamond C Zeitler M Gomez A Baroja-Mazo A Bagnall J. Inflammasome-dependent IL-1β release depends upon membrane permeabilisation. Cell Death Different. (2016) 23: 1219– 31. 10.1038/cdd.2015.176 26868913 PMC4946890 · DOI
  16. [20]Gaidt MM Hornung V. The NLRP3 inflammasome renders cell death pro-inflammatory. J Mol Biol. (2018) 430: 133– 41. 10.1016/j.jmb.2017.11.013 29203171 · DOI · Paper page
  17. [21]Mangan MS Olhava EJ Roush WR Seidel HM Glick GD Latz E Targeting the NLRP3 inflammasome in inflammatory diseases. Nat Rev Drug Discov. (2018) 17: 588– 606. 10.1038/nrd.2018.97 30026524 · DOI · Paper page
  18. [22]Bauernfeind FG Horvath G Stutz A Alnemri ES Macdonald K Speert D. Cutting edge: NF-κB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression. J Immunol. (2009) 183: 787– 91. 10.4049/jimmunol.0901363 19570822 PMC2824855 · DOI
  19. [23]Franchi L Eigenbrod T Muñozplanillo R Ozkurede U Kim YG Arindam C. Cytosolic double-stranded RNA activates the NLRP3 inflammasome via MAVS-induced membrane permeabilization and K+ efflux. J Immunol. (2014) 193: 4214– 22. 10.4049/jimmunol.1400582 25225670 PMC4185247 · DOI
  20. [24]Juliana C Fernandes-Alnemri T Kang S Farias A Qin F Alnemri ES. Non-transcriptional priming and deubiquitination regulate NLRP3 inflammasome activation. J Biol Chem. (2012) 287: 36617– 22. 10.1074/jbc.M112.407130 22948162 PMC3476327 · DOI
  21. [25]Ghonime MG Shamaa OR Das S Eldomany RA Fernandesalnemri T Alnemri ES Inflammasome priming by LPS is dependent upon ERK signaling and proteasome function. J Immunol. (2014) 192: 3881– 8. 10.4049/jimmunol.1301974 24623131 PMC3980013 · DOI
  22. [26]Py BF Kim MS Vakifahmetoglunorberg H Yuan J. Deubiquitination of NLRP3 by BRCC3 critically regulates inflammasome activity. Mol Cell. (2013) 49: 331– 8. 10.1016/j.molcel.2012.11.009 23246432 · DOI
  23. [27]Kim EH Park MJ Sun P Lee ES. Increased expression of the NLRP3 inflammasome components in patients with Behçet's disease. Journal of Inflammation. (2015) 12: 41. 10.1186/s12950-015-0086-z 26136643 PMC4487834 · DOI
  24. [28]Ozaki E Campbell M Doyle SL. Targeting the NLRP3 inflammasome in chronic inflammatory diseases: current perspectives. J Inflamm Res. (2015) 8: 15– 27. 10.2147/JIR.S51250 25653548 PMC4303395 · DOI
  25. [30]Heid ME Keyel PA Kamga C Shiva S Watkins SC Salter RD. Mitochondrial reactive oxygen species induces NLRP3-dependent lysosomal damage and inflammasome activation. J Immunol. (2013) 191: 5230– 8. 10.4049/jimmunol.1301490 24089192 PMC3833073 · DOI
  26. [32]Perregaux D Gabel CA. Interleukin-1 beta maturation and release in response to ATP and nigericin. Evidence that potassium depletion mediated by these agents is a necessary and common feature of their activity. J Biol Chem. (1994) 269: 15195– 203. 8195155
  27. [34]Okada M Matsuzawa A Yoshimura A Ichijo H. The lysosome rupture-activated TAK1-JNK pathway regulates NLRP3 inflammasome activation. J Biol Chem. (2014) 289: 32926– 36. 10.1074/jbc.M114.579961 25288801 PMC4239639 · DOI
  28. [36]Lee HM Kim JJ Kim HJ Shong M Ku BJ Jo EK. Upregulated NLRP3 inflammasome activation in patients with type 2 diabetes. Diabetes. (2013) 62: 194– 204. 10.2337/db12-0420 23086037 PMC3526026 · DOI
  29. [37]Altaf A Qu P Zhao Y Wang H Lou D Niu N. NLRP3 inflammasome in peripheral blood monocytes of acute coronary syndrome patients and its relationship with statins. Coron Artery Dis. (2015) 26: 409– 21. 10.1097/MCA.0000000000000255 25946654 · DOI
  30. [38]Patel MN Bernard WG Milev NB Cawthorn WP Figg N Hart D. Hematopoietic IKBKE limits the chronicity of inflammasome priming and metaflammation. Proc Natl Acad Sci USA. (2015) 112: 506– 11. 10.1073/pnas.1414536112 25540417 PMC4299251 · DOI
  31. [39]Peng K Liu L Wei D Lv Y Wang G Xiong W. P2X7R is involved in the progression of atherosclerosis by promoting NLRP3 inflammasome activation. Int J Mol Med. (2015) 35: 1179– 88. 10.3892/ijmm.2015.2129 25761252 PMC4380202 · DOI
  32. [40]Shao BZ Wei W Ke P Xu ZQ Zhou JX Liu C Activating cannabinoid receptor 2 alleviates pathogenesis of experimental autoimmune encephalomyelitis via activation of autophagy and inhibiting NLRP 3 inflammasome. CNS Neurosci Ther. (2014) 20: 1021– 8. 10.1111/cns.12349 25417929 PMC6492996 · DOI
  33. [41]Inoue M Williams KL Gunn MD Shinohara ML. NLRP3 inflammasome induces chemotactic immune cell migration to the CNS in experimental autoimmune encephalomyelitis. Proc Natl Acad Sci USA. (2012) 109: 10480– 5. 10.1073/pnas.1201836109 22699511 PMC3387125 · DOI
  34. [42]Cheng YL Song LQ Huang YM Xiong YW Zhang XA Sun H Effect of enterohaemorrhagic Escherichia coli O 157: H 7-specific enterohaemolysin on interleukin-1β production differs between human and mouse macrophages due to the different sensitivity of NLRP 3 activation. Immunology. (2015) 145: 258– 67. 10.1111/imm.12442 25580516 PMC4427390 · DOI
  35. [43]Guo W Liu W Jin B Geng J Li J Ding H. Asiatic acid ameliorates dextran sulfate sodium-induced murine experimental colitis via suppressing mitochondria-mediated NLRP3 inflammasome activation. Int Immunopharmacol. (2015) 24: 232– 8. 10.1016/j.intimp.2014.12.009 25523461 · DOI
  36. [44]Sun Y Zhao Y Yao J Zhao L Wu Z Wang Y. Wogonoside protects against dextran sulfate sodium-induced experimental colitis in mice by inhibiting NF-κB and NLRP3 inflammasome activation. Biochem pharmacol. (2015) 94: 142– 54. 10.1016/j.bcp.2015.02.002 25677765 · DOI
  37. [45]Kolb R Liu G-H Janowski AM Sutterwala FS Zhang W. Inflammasomes in cancer: a double-edged sword. Protein Cell. (2014) 5: 12– 20. 10.1007/s13238-013-0001-4 24474192 PMC3938856 · DOI
  38. [46]Karki R Man S Kanneganti T. Inflammasomes and cancer. Cancer Immunol Res. 5: 94– 99. 10.1158/2326-6066.CIR-16-0269 28093447 PMC5593081 · DOI
  39. [47]Ozkurede V Franchi L. Immunology in clinic review series; focus on autoinflammatory diseases: role of inflammasomes in autoinflammatory syndromes. Clin Exp Immunol. (2012) 167: 382– 90. 10.1111/j.1365-2249.2011.04535.x 22288581 PMC3374270 · DOI
  40. [50]Hu Z Murakami T Suzuki K Tamura H Kuwahara-Arai K Iba T. Antimicrobial cathelicidin peptide LL-37 inhibits the LPS/ATP-induced pyroptosis of macrophages by dual mechanism. PLoS ONE. (2014) 9: e85765. 10.1371/journal.pone.0085765 24454930 PMC3894207 · DOI
  41. [51]Liu Y Lian K Zhang L Wang R Yi F Gao C. TXNIP mediates NLRP3 inflammasome activation in cardiac microvascular endothelial cells as a novel mechanism in myocardial ischemia/reperfusion injury. Basic Res Cardiol. (2014) 109: 415. 10.1007/s00395-014-0415-z 25015733 · DOI
  42. [52]Jiang H He H Chen Y Huang W Cheng J Ye J. Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders. J Exp Med. (2017) 214: 3219– 38. 10.1084/jem.20171419 29021150 PMC5679172 · DOI
  43. [53]He Y Varadarajan S Muñoz-Planillo R Burberry A Nakamura Y Núñez G. 3, 4-methylenedioxy-β-nitrostyrene inhibits NLRP3 inflammasome activation by blocking assembly of the inflammasome. J Biol Chem. (2014) 289: 1142– 50. 10.1074/jbc.M113.515080 24265316 PMC3887181 · DOI
  44. [54]Perregaux DG McNiff P Laliberte R Hawryluk N Peurano H Stam E. Identification and characterization of a novel class of interleukin-1 post-translational processing inhibitors. J Pharmacol Exp Ther. (2001) 299: 187– 97. 11561079
  45. [55]Marchetti C Toldo S Chojnacki J Mezzaroma E Liu K Salloum FN Pharmacologic inhibition of the NLRP3 inflammasome preserves cardiac function after ischemic and non-ischemic injury in the mouse. J Cardiovasc Pharmacol. (2015) 66: 1– 8. 10.1097/FJC.0000000000000247 25915511 PMC4500673 · DOI
  46. [56]Marchetti C Chojnacki J Toldo S Mezzaroma E Tranchida N Rose SW A novel pharmacologic inhibitor of the NLRP3 inflammasome limits myocardial injury following ischemia-reperfusion in the mouse. J Cardiovasc Pharmacol. (2014) 63: 316– 22. 10.1097/FJC.0000000000000053 24336017 PMC3980088 · DOI
  47. [57]Kuwar R Rolfe A Di L Xu H He L Jiang Y. A novel small molecular NLRP3 inflammasome inhibitor alleviates neuroinflammatory response following traumatic brain injury. J Neuroinflamm. (2019) 16: 81. 10.1186/s12974-019-1471-y 30975164 PMC6458637 · DOI
  48. [58]Liu W Guo W Wu J Luo Q Tao F Gu Y. A novel benzo[d]imidazole derivate prevents the development of dextran sulfate sodium-induced murine experimental colitis via inhibition of NLRP3 inflammasome. Biochem Pharmacol. (2013) 85: 1504– 12. 10.1016/j.bcp.2013.03.008 23506741 · DOI
  49. [59]Juliana C Fernandes-Alnemri T Wu J Datta P Solorzano L Yu J-W. Anti-inflammatory compounds parthenolide and Bay 11–7082 are direct inhibitors of the inflammasome. J Biol Chem. (2010) 285: 9792– 802. 10.1074/jbc.M109.082305 20093358 PMC2843228 · DOI
  50. [60]Saadane A Masters S Didonato J Li J Berger M. Parthenolide inhibits IκB Kinase, NF-κB activation, and inflammatory response in cystic fibrosis cells and mice. Am J Respir Cell Mol Biol. (2007) 36: 728– 36. 10.1165/rcmb.2006-0323OC 17272824 PMC1899341 · DOI
  51. [61]Boxer MB Shen M Auld DS Wells JA Thomas CJ A Small Molecule Inhibitor of Caspase 1. Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda, MD: National Center for Biotechnology Information (2010). 21735610
  52. [62]Rudolphi K Gerwin N Verzijl N Kraan PVD Berg WVD. Pralnacasan, an inhibitor of interleukin-1β converting enzyme, reduces joint damage in two murine models of osteoarthritis. Osteoarthritis Cartilage. (2003) 11: 738– 46. 10.1016/S1063-4584(03)00153-5 13129693 · DOI
  53. [63]Wannamaker W Davies R Namchuk M Pollard J Ford P Ku G (S)-1-((S)-2-{[1-(4-Amino-3-chloro-phenyl)-methanoyl]-amino}-3,3-dimethyl-butanoyl)-pyrrolidine-2-carboxylic acid ((2R,3S)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-amide (VX-765), an Orally Available Selective Interleukin (IL)-Converting Enzyme/Caspase-1 Inhi. J Pharmacol Exp Ther. (2007) 321: 509– 16. 10.1124/jpet.106.111344 17289835 · DOI
  54. [64]Strickson S Campbell DG Emmerich CH Knebel A Plater L Ritorto MS. The anti-inflammatory drug BAY 11–7082 suppresses the MyD88-dependent signalling network by targeting the ubiquitin system. Biochem J. (2013) 451(Pt 3): 427– 37. 10.1042/BJ20121651 23441730 PMC3685219 · DOI
  55. [65]Meng X Martinez MA Raymond-Stintz MA Winter SS Wilson BS. IKK inhibitor bay 11-7082 induces necroptotic cell death in precursor-B acute lymphoblastic leukaemic blasts. Br J Haematol. (2010) 148: 487– 90. 10.1111/j.1365-2141.2009.07988.x 19958360 · DOI
  56. [66]Krishnan N Bencze G Cohen P Tonks NK. The anti-inflammatory compound BAY 11–7082 is a potent inhibitor of Protein Tyrosine Phosphatases. FEBS J. (2013) 280: 2830– 41. 10.1111/febs.12283 23578302 PMC3712534 · DOI
  57. [68]Coll RC Hill JR Day CJ Zamoshnikova A Boucher D Massey NL. MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome inhibition. Nat Chem Biol. (2019) 15: 556– 9. 10.1038/s41589-019-0277-7 31086327 · DOI
  58. [69]Huang Y Jiang H Chen Y Wang X Yang Y Tao J. Tranilast directly targets NLRP3 to treat inflammasome-driven diseases. EMBO Mol Med. (2018) 10: e8689. 10.15252/emmm.201708689 29531021 PMC5887903 · DOI
  59. [70]Marchetti C Swartzwelter B Gamboni F Neff CP Richter K Azam T. OLT1177, a β-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation. Proc Natl Acad Sci USA. (2018) 115: E1530– 9. 10.1073/pnas.1716095115 29378952 PMC5816172 · DOI
  60. [71]He H Jiang H Chen Y Ye J Wang A Wang C. Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity. Nat Commun. (2018) 9: 2550. 10.1038/s41467-018-04947-6 29959312 PMC6026158 · DOI · Paper page
  61. [72]Riddle MC. Editorial: sulfonylureas differ in effects on ischemic preconditioning–is it time to retire glyburide? J Clin Endocrinol Metab. (2003) 88: 528– 30. 10.1210/jc.2002-021971 12574174 · DOI
  62. [73]Ashcroft FM. ATP-sensitive potassium channelopathies: focus on insulin secretion. J Clin Invest. (2005) 115: 2047– 58. 10.1172/JCI25495 16075046 PMC1180549 · DOI
  63. [74]Mariathasan S Newton K Monack DM Vucic D French DM Lee WP. Differential activation of the inflammasome by caspase-1 adaptors ASC and Ipaf. Nature. (2004) 430: 213– 8. 10.1038/nature02664 15190255 · DOI
  64. [75]Hamon Y Luciani MF Becq F Verrier B Rubartelli A Chimini G. Interleukin-1beta secretion is impaired by inhibitors of the Atp binding cassette transporter, ABC1. Blood. (1997) 90: 2911– 5. 10.1182/blood.V90.8.2911 9376570 · DOI
  65. [76]Lottaz D Beleznay Z Bickel M. Inhibition of ATP-binding cassette transporter downregulates interleukin-1beta-mediated autocrine activation of human dermal fibroblasts. J Invest Dermatol. (2001) 117: 871– 6. 10.1046/j.0022-202x.2001.01451.x 11676825 · DOI
  66. [77]Fulp J He L Toldo S Jiang Y Boice A Guo C. Structural insights of benzenesulfonamide analogues as NLRP3 inflammasome inhibitors: design, synthesis, and biological characterization. J Med Chem. (2018) 61: 5412– 23. 10.1021/acs.jmedchem.8b00733 29877709 PMC6225534 · DOI
  67. [78]Yin J Zhao F Chojnacki JE Fulp J Klein WL Zhang S. NLRP3 inflammasome inhibitor ameliorates amyloid pathology in a mouse model of Alzheimer's disease. Mol Neurobiol. (2018) 55: 1977– 87. 10.1007/s12035-017-0467-9 28255908 PMC5585057 · DOI
  68. [79]Heinrich M Robles M West JE Ortiz de Montellano BR Rodriguez E. Ethnopharmacology of Mexican asteraceae (compositae). Ann Rev Pharmacol Toxicol. (1998) 38: 539– 65. 10.1146/annurev.pharmtox.38.1.539 9597165 · DOI
  69. [80]Guzman ML Rossi RM Neelakantan S Li X Corbett CA Hassane DC. An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood. (2007) 110: 4427– 35. 10.1182/blood-2007-05-090621 17804695 PMC2234793 · DOI
  70. [81]D'anneo A Carlisi D Lauricella M Puleio R Martinez R Di Bella S. Parthenolide generates reactive oxygen species and autophagy in MDA-MB231 cells. A soluble parthenolide analogue inhibits tumour growth and metastasis in a xenograft model of breast cancer. Cell Death Dis. (2013) 4: e891. 10.1038/cddis.2013.415 24176849 PMC3920954 · DOI
  71. [82]Mackenzie SH Schipper JL Clark AC. The potential for caspases in drug discovery. Curr Opin Drug Discov Devel. (2010) 13: 568– 76. 10.4049/jimmunol.168.6.3024 20812148 PMC3289102 · DOI
  72. [83]Siegmund B Zeitz M. Pralnacasan (vertex pharmaceuticals). IDrugs. (2003) 6: 154– 8. 12789619
  73. [84]Strand V Sokolove J. Randomized controlled trial design in rheumatoid arthritis: the past decade. Arthritis Res Ther. (2009) 11: 205. 10.1186/ar2555 19232061 PMC2688216 · DOI
  74. [85]Fischer U Schulzeosthoff K. Apoptosis-based therapies and drug targets. Cell Death Different. (2005) 12(Suppl 1): 942– 61. 10.1038/sj.cdd.4401556 15665817 · DOI
  75. [86]Maroso M Balosso S Ravizza T Liu J Bianchi ME Vezzani A. Interleukin-1 type 1 receptor/Toll-like receptor signalling in epilepsy: the importance of IL-1beta and high-mobility group box 1. J Int Med. (2011) 270: 319– 26. 10.1111/j.1365-2796.2011.02431.x 21793950 · DOI
  76. [87]Flores J Noël A Foveau B Lynham J Lecrux C Leblanc AC. Caspase-1 inhibition alleviates cognitive impairment and neuropathology in an Alzheimer's disease mouse model. Nat Commun. (2018) 9: 3916. 10.1038/s41467-018-06449-x 30254377 PMC6156230 · DOI
  77. [88]Audia JP Yang XM Crockett ES Housley N Haq EU O'Donnell K. Caspase-1 inhibition by VX-765 administered at reperfusion in P2Y12 receptor antagonist-treated rats provides long-term reduction in myocardial infarct size and preservation of ventricular function. Basic Res Cardiol. (2018) 113: 32. 10.1007/s00395-018-0692-z 29992382 PMC6396295 · DOI
  78. [89]Kerr ID Lee JH Farady CJ Marion R Rickert M Sajid M. Vinyl sulfones as antiparasitic agents and a structural basis for drug design. J Biol Chem. (2009) 284: 25697– 703. 10.1074/jbc.M109.014340 19620707 PMC2757971 · DOI
  79. [90]Daniels MJ Rivers-Auty J Schilling T Spencer NG Watremez W Fasolino V. Fenamate NSAIDs inhibit the NLRP3 inflammasome and protect against Alzheimer's disease in rodent models. Nat Commun. (2016) 7: 12504. 10.1038/ncomms12504 27509875 PMC4987536 · DOI
  80. [91]Dempsey C Araiz AR Bryson K Finucane O Larkin C Mills E. Inhibiting the NLRP3 inflammasome with MCC950 promotes non-phlogistic clearance of amyloid-β and cognitive function in APP/PS1 mice. Brain Behav Immun. (2017) 61: 306– 16. 10.1016/j.bbi.2016.12.014 28003153 · DOI · Paper page
  81. [92]Vande Walle L Stowe IB Šácha P Lee BL Demon D Fossoul A MCC950/CRID3 potently targets the NACHT domain of wildtype NLRP3 but not disease-associated mutants for inflammasome inhibition. bioRxiv. (2019) 634493 10.1101/634493 PMC6762198 31525186 · DOI
  82. [93]Primiano MJ Lefker BA Bowman MR Bree AG Hubeau C Bonin PD. Efficacy and pharmacology of the NLRP3 inflammasome inhibitor CP-456,773 (CRID3) in murine models of dermal and pulmonary inflammation. J Immunol. (2016) 197: 2421– 33. 10.4049/jimmunol.1600035 27521339 · DOI
  83. [94]Gordon R Albornoz EA Christie DC Langley MR Kumar V Mantovani S. Inflammasome inhibition prevents α-synuclein pathology and dopaminergic neurodegeneration in mice. Sci Trans Med. (2018) 10: eaah4066. 10.1126/scitranslmed.aah4066 30381407 PMC6483075 · DOI · Paper page
  84. [95]Ma T Thiagarajah JR Yang H Sonawane ND Folli C Galietta LJ. Thiazolidinone CFTR inhibitor identified by high-throughput screening blocks cholera toxin–induced intestinal fluid secretion. J Clin Invest. (2002) 110: 1651– 8. 10.1172/JCI16112 12464670 PMC151633 · DOI
  85. [96]Sonawane N Verkman A. Thiazolidinone CFTR inhibitors with improved water solubility identified by structure–activity analysis. Bioorgan Med Chem. (2008) 16: 8187– 95. 10.1016/j.bmc.2008.07.044 18691893 PMC2577561 · DOI
  86. [97]Darakhshan S Pour AB. Tranilast: a review of its therapeutic applications. Pharmacol Res. (2015) 91: 15– 28. 10.1016/j.phrs.2014.10.009 25447595 · DOI
  87. [98]Konneh M. Tranilast Kissei pharmaceutical. IDrugs. (1998) 1: 141– 6. 18465519
  88. [99]Platten M Ho PP Youssef S Fontoura P Garren H Hur EM. Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite. Science. (2005) 310: 850– 5. 10.1126/science.1117634 16272121 · DOI
  89. [100]Toldo S Abbate A. The NLRP3 inflammasome in acute myocardial infarction. Nat Rev Cardiol. (2018) 15: 203– 14. 10.1038/nrcardio.2017.161 29143812 · DOI
  90. [101]Kadota S Basnet P Ishii E Tamura T Namba T. Antibacterial activity of trichorabdal A from Rabdosia trichocarpa against Helicobacter pylori. Zentralblatt Bakteriol. (1997) 286: 63– 7. 10.1016/S0934-8840(97)80076-X 9241802 · DOI
  91. [102]Kuo L-M Kuo C-Y Lin C-Y Hung M-F Shen J-J Hwang T-L. Intracellular glutathione depletion by oridonin leads to apoptosis in hepatic stellate cells. Molecules. (2014) 19: 3327– 44. 10.3390/molecules19033327 24647034 PMC6270846 · DOI
  92. [103]Ding Y Ding C Ye N Liu Z Wold EA Chen H. Discovery and development of natural product oridonin-inspired anticancer agents. Eur J Med Chem. (2016) 122: 102– 17. 10.1016/j.ejmech.2016.06.015 27344488 PMC5003635 · DOI
  93. [104]Fujita E Nagao Y Kaneko K Nakazawa S Kuroda H. The antitumor and antibacterial activity of the Isodon diterpenoids. Chem Pharm Bull. (1976) 24: 2118– 27. 10.1248/cpb.24.2118 991362 · DOI
  94. [105]Huang J Wu L Tashiro S-i Onodera S Ikejima T A comparison of the signal pathways between the TNFα-and oridonin-induced Murine L929 fibrosarcoma cell death. Acta Med Okayama. (2005) 59: 261– 70. 10.18926/AMO/31960 16418769 · DOI
  95. [106]Xu Y Xue Y Wang Y Feng D Lin S Xu L. Multiple-modulation effects of Oridonin on the production of proinflammatory cytokines and neurotrophic factors in LPS-activated microglia. Int Immunopharmacol. (2009) 9: 360– 5. 10.1016/j.intimp.2009.01.002 19185062 · DOI
  96. [107]Zhao G Zhang T Ma X Jiang K Wu H Qiu C. Oridonin attenuates the release of pro-inflammatory cytokines in lipopolysaccharide-induced RAW264. 7 cells and acute lung injury. Oncotarget. (2017) 8: 68153. 10.18632/oncotarget.19249 28978105 PMC5620245 · DOI
  97. [108]Wang S Zhang Y Saas P Wang H Xu Y Chen K Oridonin's therapeutic effect: Suppressing T h1/T h17 simultaneously in a mouse model of C rohn's disease. J Gastroenterol Hepatol. (2015) 30: 504– 12. 10.1111/jgh.12710 25211373 · DOI
  98. [109]Wang S Yang H Yu L Jin J Qian L Zhao H. Oridonin attenuates Aβ1–42-induced neuroinflammation and inhibits NF-κB pathway. PLoS ONE. (2014) 9: e104745. 10.1371/journal.pone.0104745 25121593 PMC4133239 · DOI
  99. [110]Zhang ZY Daniels R Schluesener HJ. Oridonin ameliorates neuropathological changes and behavioural deficits in a mouse model of cerebral amyloidosis. J Cell Mol Med. (2013) 17: 1566– 76. 10.1111/jcmm.12124 24034629 PMC3914648 · DOI
  100. [111]Jiang D Chen S Sun R Zhang X Wang D. The NLRP3 inflammasome: role in metabolic disorders and regulation by metabolic pathways. Cancer Lett. (2018) 419: 8– 19. 10.1016/j.canlet.2018.01.034 29339210 · DOI
  101. [112]Dinarello CA van der Meer JW. Treating inflammation by blocking interleukin-1 in humans. Semin Immunol. (2013) 25: 469– 84. 10.1016/j.smim.2013.10.008 24275598 PMC3953875 · DOI
  102. [113]Nowarski R Jackson R Gagliani N de Zoete MR Palm NW Bailis W. Epithelial IL-18 equilibrium controls barrier function in colitis. Cell. (2015) 163: 1444– 56. 10.1016/j.cell.2015.10.072 26638073 PMC4943028 · DOI
  103. [114]Lu B Nakamura T Inouye K Li J Tang Y Lundbäck P. Novel role of PKR in inflammasome activation and HMGB1 release. Nature. (2012) 488: 670– 4. 10.1038/nature11290 22801494 PMC4163918 · DOI
  104. [115]Kanneganti A Malireddi RS Saavedra PH Walle LV Van Gorp H Kambara H. GSDMD is critical for autoinflammatory pathology in a mouse model of Familial Mediterranean Fever. Journal of Experimental Medicine. (2018) 215: 1519– 29. 10.1084/jem.20172060 29793924 PMC5987922 · DOI
  105. [116]Xiao J Wang C Yao J-C Alippe Y Xu C Kress D. Gasdermin D mediates the pathogenesis of neonatal-onset multisystem inflammatory disease in mice. PLoS Biol. (2018) 16: e3000047. 10.1371/journal.pbio.3000047 30388107 PMC6235378 · DOI
  106. [117]Gaidt MM Hornung V. Pore formation by GSDMD is the effector mechanism of pyroptosis. EMBO J. (2016) 35: 2167– 9. 10.15252/embj.201695415 27572465 PMC5069554 · DOI
  107. [118]Liu X Zhang Z Ruan J Pan Y Magupalli VG Wu H. Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores. Nature. (2016) 535: 153– 8. 10.1038/nature18629 27383986 PMC5539988 · DOI · Paper page
  108. [119]Salvador JP Vilaplana L Marco MP. Nanobody: outstanding features for diagnostic and therapeutic applications. Anal Bioanal Chem. (2019) 411: 1703– 13. 10.1007/s00216-019-01633-4 30734854 · DOI
  109. [120]Konning D Zielonka S Grzeschik J Empting M Valldorf B Krah S. Camelid and shark single domain antibodies: structural features and therapeutic potential. Curr Opin Struct Biol. (2017) 45: 10– 6. 10.1016/j.sbi.2016.10.019 27865111 · DOI · Paper page

Cited by

Sorted by citations

Authors
Zahid, A., Li, B., Kombe, A. J. K., Jin, T., & Tao, J.
Affiliations
University of Science and Technology of China (CN)
Corresponding author
Jin, Tengchuan
ORCID
Venue
Frontiers in Immunology
Publisher
Frontiers Media SA
Published
2019-10-25
Volume
10
Pages
2538-2538
ISSN
1664-3224 (ISSN-L)
DOI
10.3389/fimmu.2019.02538
PMC
PMC6842943
OpenAlex
W2982061867
Cited by
671
References
123
Citations by year
2026: 49 · 2025: 94 · 2024: 107 · 2023: 101 · 2022: 129 · 2021: 122 · 2020: 69
FWCI
7.09
Type
journal article
Language
en
Open access
Licence
Locations
  • Frontiers in Immunology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Natural Science Foundation of China (201904a07020103, 81771774)
  • Natural Science Foundation of Anhui Province (1708085MH191)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Inflammasome and immune disorders
  • Life Sciences › Immunology and Microbiology › Immunology › Immune Response and Inflammation
  • Health Sciences › Medicine › Hematology › Autoimmune and Inflammatory Disorders Research
Keywords
NLRP3 inflammasome, inflammasome inhibitors, NLRP3, ASC, pyroptosis, inflammatory cytokines, innate immunity, diabetes mellitus, atherosclerosis, metabolic syndrome, neurodegenerative diseases, cardiovascular disease, mechanism of action
MeSH terms
NLR Family, Pyrin Domain-Containing 3 Protein, Animals, Dipeptides, Glyburide, Humans, Nitriles, Sulfones, Inflammasomes, para-Aminobenzoates, ortho-Aminobenzoates

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review